By Sherri
Oslick —

About
Court
Report:  Each week we will report briefly on recently filed
biotech and pharma cases.

AstraZeneca Pharmaceuticals LP et al. v. Glenmark Generics Inc.
USA
1:10-cv-00543; filed June 21, 2010 in the District
Court of Delaware

• Plaintiffs:  AstraZeneca Pharmaceuticals LP;
AstraZeneca UK Ltd.; IPR Pharmaceuticals Inc.; Shionogi Seiyaku Kabushiki
Kaisha
• Defendant:  Glenmark Generics Inc. USA

Infringement of U.S. Patent No. RE37,314 ("Pyrimidine
Derivatives," issued August 7, 2001) following a Paragraph IV
certification as part of Glenmark's filing of an ANDA to manufacture a generic
version of AstraZeneca's Crestor® (rosuvastatin calcium, used to treat high
cholesterol).  View the complaint here.

Pfizer Inc. et al. v. Mylan Inc. et al.
1:10-cv-00094; filed June 18, 2010 in the Northern
District of West Virginia

• Plaintiffs:  Pfizer Inc.; Pharmacia & Upjohn
Co.; Pharmacia & Upjohn Company LLC; Sugen, Inc.; C.P. Pharmaceuticals
International C.V.
• Defendants:  Mylan Inc.; Mylan Pharmaceuticals
Inc.

Infringement of U.S. Patent Nos. 6,573,293 ("Pyrrole
Substituted 2-Indolinone Protein Kinase Inhibitors," issued June 3, 2003),
7,125,905 (same title, issued October 24, 2006), and 7,211,600 ("Methods
of Modulating c-kit Tyrosine Protein Kinase Function with Indolinone Compounds,"
issued May 1, 2007) following a Paragraph IV certification as part of Mylan's
filing of an ANDA to manufacture a generic version of Pfizer's Sutent®
(sunitinib malate, used to treat gastrointestinal stromal tumor and advanced
renal cell carcinoma).  View the
complaint here.

Abbott Laboratories et al. v. Sandoz Inc.
1:10-cv-00538; filed June 18, 2010 in the District
Court of Delaware

• Plaintiffs:  Abbott Laboratories; Abbott
Respiratory LLC
• Defendant:  Sandoz Inc.

Infringement of U.S. Patent Nos. U.S. Patent Nos.
6,080,428 ("Nicotinic Acid Compositions for Treating Hyperlipidemia and
Related Methods Therefor," issued June 27, 2000), 6,469,035 ("Methods
of Pretreating Hyperlipidemic Individuals with a Flush Inhibiting Agent Prior
to the Start of Single Daily Dose Nicotinic Acid Therapy to Reduce Flushing
Provoked by Nicotinic Acid," issued October 22, 2002), and 6,818,229 ("Intermediate
Release Nicotinic Acid Compositions for Treating Hyperlipidemia," issued
November 16, 2004) following a Paragraph IV certification as part of Sandoz's
filing of an ANDA to manufacture a generic version of Abbott's Niaspan® (niacin
extended-release tablets, used to treat hypercholesterolemia).  View the complaint here.

Schering Corporation et al. v. Mylan Pharmaceuticals Inc. et
al.
2:10-cv-03085; filed June 16, 2010 in the District
Court of Delaware

• Plaintiffs:  Schering Corp.; MSP Singapore
Co. LLC
• Defendants:  Mylan Pharmaceuticals Inc.; Mylan
Inc.

Infringement of U.S. Patent Nos. RE37,721 ("Hydroxy-substituted
Azetidinone Compounds Useful as Hypocholesterolemic Agents," issued May 8,
2002) and 5,846,966 ("Combinations of Hydroxy-Substituted Azetidinone
Compounds and HMG CoA Reductase Inhibitors," issued December 8, 1998)
following a Paragraph IV certification as part of Mylan's filing of an ANDA to
manufacture a generic version of Plaintiffs' Zetia® (ezetimib, used to treat
elevated cholesterol levels).  View
the complaint here.